Shai Izraeli

GLI3 is not mutated commonly in sporadic medulloblastomas.

Molecular medicine--an overview.

Cancer research--from bench to bedside.

Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Congenital syndromes and leukemia: clues to pathogenesis.

Kidney, blood, and endothelium: developmental expression of stem cell leukemia during nephrogenesis.

Sil overexpression in lung cancer characterizes tumors with increased mitotic activity.

Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients.

Minimal residual disease in childhood acute lymphoblastic leukemia: current status and challenges.

Leukaemia -- a developmental perspective.

Histone deacetylase inhibitors--a new tool to treat cancer.

Co-existence of multiple subclones in TEL-AML1 at diagnosis of acute lymphoblastic leukaemia in association with submicroscopic deletion of AML1.

Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer.

Sil phosphorylation in a Pin1 binding domain affects the duration of the spindle checkpoint.

The proto-oncogene ERG in megakaryoblastic leukemias.

Chromosome copy number and leukemia-lessons from Down's syndrome.

Perspective: chromosomal aneuploidy in leukemia--lessons from down syndrome.

Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas.

Myeloid dysplasia in familial 3-methylglutaconic aciduria.

Molecular pathways regulating pro-migratory effects of Hedgehog signaling.

Prediction of chromosomal aneuploidy from gene expression data.

Down's syndrome as a model of a pre-leukemic condition.

The SCL 3' enhancer responds to Hedgehog signaling during hemangioblast specification.

The SIL gene is essential for mitotic entry and survival of cancer cells.

STOP: searching for transcription factor motifs using gene expression.

Trisomy of chromosome 21 in leukemogenesis.

High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS.

Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.

Biased exonization of transposed elements in duplicated genes: A lesson from the TIF-IA gene.

Integration of a palliative and terminal care center into a comprehensive pediatric oncology department.

ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.

Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome.

The mitotic checkpoint gene, SIL is regulated by E2F1.

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.

Trisomy 21 tilts the balance.

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.

Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain.

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

Constitutional aneuploidy and cancer predisposition.

Acute lymphoblastic leukemia in children: correlation of musculoskeletal manifestations and immunophenotypes.

ERG is a megakaryocytic oncogene.

Extended triple intrathecal therapy in children with T-cell acute lymphoblastic leukaemia: a report from the Israeli National ALL-Studies.

Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry.

A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.

A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.

Where can biology of childhood ALL be attacked by new compounds?

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.

Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.

Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?

Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfürt-Münster study group.

Similar yet different.

Therapy-related acute myeloid leukemia with t(2;11)(q37;q23) after treatment for osteosarcoma.

The Stil protein regulates centrosome integrity and mitosis through suppression of Chfr.

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.

ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.

Large-scale analysis of chromosomal aberrations in cancer karyotypes reveals two distinct paths to aneuploidy.

A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells.

STIL is required for centriole duplication in human cells.

DYRK1A in Down syndrome: an oncogene or tumor suppressor?

Spontaneous remission of childhood acute marrow fibrosis and megakaryoblastic leukemia.

Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability.

Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.

Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia.

Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.